文献速递支持与姑息治疗

Quizartinib单药治疗复发或难治性急性髓系白血病的II期试验

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2018-05-31

这项开放标签、多中心、单臂II期试验评估了口服FLT3抑制剂Quizartinib在复发或难治性急性髓系白血病患者中的疗效与安全性,共入组333例患者。结果显示,FLT3-ITD阳性患者的复合完全缓解率在队列1为56%、队列2为46%,常见≥3级治疗相关不良事件包括发热性中性粒细胞减少和血细胞减少。

要点

  • Quizartinib在FLT3-ITD阳性复发/难治AML中显示较高复合完全缓解率。
  • 常见≥3级治疗相关不良事件为发热性中性粒细胞减少、贫血和血小板减少。
  • QTcF延长需关注,初始200mg/d因QTcF延长而调整为男性135mg/d、女性90mg/d。

核心结论

  • 单药Quizartinib在复发或难治性急性髓系白血病中高度活跃且总体耐受良好,尤其是FLT3-ITD突变患者。

研究设计与样本

  • 开放标签、多中心、单臂II期试验,在美国、欧洲和加拿大的76家医院和癌症中心开展。
  • 入组333例患者,分为两个预设独立队列:队列1为≥60岁且一线治疗后1年内复发/难治者(157例),队列2为≥18岁且挽救化疗或造血干细胞移植后复发/难治者(176例)。
  • FLT3-ITD等位基因频率>10%定义为FLT3-ITD阳性,其余为阴性。
  • 主要终点为复合完全缓解率和完全缓解率,疗效与安全性分析纳入至少接受一剂Quizartinib的患者(意向治疗人群)。

主要发现

  • 队列1中,FLT3-ITD阳性患者复合完全缓解率为56%(63/112),FLT3-ITD阴性患者为36%(16/44);完全缓解率分别为3%(3例)和5%(2例)。
  • 队列2中,FLT3-ITD阳性患者复合完全缓解率为46%(62/136),FLT3-ITD阴性患者为30%(12/40);完全缓解率分别为4%(5例)和3%(1例)。
  • 全部333例中,≥5%患者发生的≥3级治疗相关治疗中出现的不良事件包括发热性中性粒细胞减少23%(76例)、贫血23%(75例)、血小板减少12%(39例)、QTcF延长10%(33例)等。
  • 严重不良事件≥5%包括发热性中性粒细胞减少38%(126例)、AML进展22%(73例)、肺炎12%(40例)、QTcF延长10%(33例)、脓毒症8%(25例)、发热5%(18例)。
  • 研究治疗期间(含30天随访)共125例(38%)死亡,其中18例(5%)死于研究者认为与治疗相关的不良事件。

关键数值与推荐

  • FLT3-ITD阳性定义为等位基因频率>10%。
  • 初始17例患者接受Quizartinib 200 mg每日一次,因部分患者QTcF间期较基线延长>60 ms,后续所有患者剂量调整为男性135 mg每日一次、女性90 mg每日一次。

临床怎么用

  • 对于复发或难治性FLT3-ITD阳性急性髓系白血病患者,单药Quizartinib可作为具有临床活性的靶向治疗选择。
  • 治疗期间需密切监测血细胞计数和QTcF间期,并管理发热性中性粒细胞减少等不良事件。

局限性

  • 本研究为单臂II期试验,无随机对照,结论需III期研究进一步验证。
  • 初始剂量因QTcF延长而调整,后续研究将评估更低起始剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia. METHODS: We did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed. FINDINGS: Between Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [<1%]) and hepatic failure (two [1%]). In total, 125 (38%) of 333 patients died within the study treatment period, including the 30-day follow-up. 18 (5%) patients died because of an adverse event considered by the investigator to be treatment related (ten [6%] of 157 patients in cohort 1 and eight [5%] of 176 in cohort 2. INTERPRETATION: Single-agent quizartinib was shown to be highly active and generally well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses. FUNDING: Ambit Biosciences/Daiichi Sankyo.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018. PMID: 29859851. doi:10.1016/S1470-2045(18)30240-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。